雄激素受体和叉头框蛋白 A1 在大汗腺癌中的过表达。
Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
机构信息
Department of Breast Surgery, National Hospital Organization, Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan.
出版信息
Anticancer Res. 2014 Mar;34(3):1261-7.
AIM
Apocrine breast carcinoma often lacks estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor type-2 (HER2) expression. Accordingly, development of a new treatment strategy is important for this type of cancer. The growth stimulus through the androgen receptor (AR) can be a candidate for targeted treatment. Therefore, we examined the factors related to AR transcription.
MATERIALS AND METHODS
We immunohistochemically evaluated 54 apocrine cancer lesions for ER, PgR, AR, HER2, Ki-67, forkhead-box protein A1 (FOXA1), and prostate-specific antigen (PSA) expression.
RESULTS
ER, PgR, and HER2 were expressed at a low level, thus 44 out of 54 (81.4%) cases were of triple-negative breast cancer. AR, PSA and FOXA1 were expressed in 100% (54/54), 48% (26/54) and 93% (50/54) of cases, respectively.
CONCLUSION
Most of apocrine breast carcinomas were immunohistochemically-positive for AR and FOXA1. Anti-androgenic therapies can potentially serve as a cancer-targeting therapy for apocrine breast carcinoma.
目的
大汗腺癌常缺乏雌激素受体（ER）、孕激素受体（PgR）和人表皮生长因子受体 2（HER2）的表达。因此，为这种类型的癌症开发新的治疗策略非常重要。雄激素受体（AR）的生长刺激可以作为靶向治疗的候选物。因此，我们研究了与 AR 转录相关的因素。
材料和方法
我们用免疫组织化学方法评估了 54 例大汗腺癌病变中 ER、PgR、AR、HER2、Ki-67、叉头框蛋白 A1（FOXA1）和前列腺特异性抗原（PSA）的表达。
结果
ER、PgR 和 HER2 的表达水平较低，因此 54 例中有 44 例（81.4%）为三阴性乳腺癌。AR、PSA 和 FOXA1 的表达率分别为 100%（54/54）、48%（26/54）和 93%（50/54）。
结论
大多数大汗腺癌的 AR 和 FOXA1 免疫组织化学阳性。抗雄激素治疗可能成为大汗腺癌的一种靶向治疗方法。
Zotero 插件